Prospective isolation of chondroprogenitors from human iPSCs based on cell surface markers identified using a CRISPR-Cas9-generated reporter.


Journal

Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581

Informations de publication

Date de publication:
18 02 2020
Historique:
received: 08 07 2019
accepted: 11 02 2020
revised: 05 02 2020
entrez: 20 2 2020
pubmed: 20 2 2020
medline: 16 3 2021
Statut: epublish

Résumé

Articular cartilage shows little or no capacity for intrinsic repair, generating a critical need of regenerative therapies for joint injuries and diseases such as osteoarthritis. Human-induced pluripotent stem cells (hiPSCs) offer a promising cell source for cartilage tissue engineering and in vitro human disease modeling; however, off-target differentiation remains a challenge during hiPSC chondrogenesis. Therefore, the objective of this study was to identify cell surface markers that define the true chondroprogenitor population and use these markers to purify iPSCs as a means of improving the homogeneity and efficiency of hiPSC chondrogenic differentiation. We used a CRISPR-Cas9-edited COL2A1-GFP knock-in reporter hiPSC line, coupled with a surface marker screen, to identify a novel chondroprogenitor population. Single-cell RNA sequencing was then used to analyze the distinct clusters within the population. An unpaired t test with Welch's correction or an unpaired Kolmogorov-Smirnov test was performed with significance reported at a 95% confidence interval. Chondroprogenitors expressing CD146, CD166, and PDGFRβ, but not CD45, made up an average of 16.8% of the total population. Under chondrogenic culture conditions, these triple-positive chondroprogenitor cells demonstrated decreased heterogeneity as measured by single-cell RNA sequencing with fewer clusters (9 clusters in unsorted vs. 6 in sorted populations) closer together. Additionally, there was more robust and homogenous matrix production (unsorted: 1.5 ng/ng vs. sorted: 19.9 ng/ng sGAG/DNA; p < 0.001) with significantly higher chondrogenic gene expression (i.e., SOX9, COL2A1, ACAN; p < 0.05). Overall, this study has identified a unique hiPSC-derived subpopulation of chondroprogenitors that are CD146

Sections du résumé

BACKGROUND
Articular cartilage shows little or no capacity for intrinsic repair, generating a critical need of regenerative therapies for joint injuries and diseases such as osteoarthritis. Human-induced pluripotent stem cells (hiPSCs) offer a promising cell source for cartilage tissue engineering and in vitro human disease modeling; however, off-target differentiation remains a challenge during hiPSC chondrogenesis. Therefore, the objective of this study was to identify cell surface markers that define the true chondroprogenitor population and use these markers to purify iPSCs as a means of improving the homogeneity and efficiency of hiPSC chondrogenic differentiation.
METHODS
We used a CRISPR-Cas9-edited COL2A1-GFP knock-in reporter hiPSC line, coupled with a surface marker screen, to identify a novel chondroprogenitor population. Single-cell RNA sequencing was then used to analyze the distinct clusters within the population. An unpaired t test with Welch's correction or an unpaired Kolmogorov-Smirnov test was performed with significance reported at a 95% confidence interval.
RESULTS
Chondroprogenitors expressing CD146, CD166, and PDGFRβ, but not CD45, made up an average of 16.8% of the total population. Under chondrogenic culture conditions, these triple-positive chondroprogenitor cells demonstrated decreased heterogeneity as measured by single-cell RNA sequencing with fewer clusters (9 clusters in unsorted vs. 6 in sorted populations) closer together. Additionally, there was more robust and homogenous matrix production (unsorted: 1.5 ng/ng vs. sorted: 19.9 ng/ng sGAG/DNA; p < 0.001) with significantly higher chondrogenic gene expression (i.e., SOX9, COL2A1, ACAN; p < 0.05).
CONCLUSIONS
Overall, this study has identified a unique hiPSC-derived subpopulation of chondroprogenitors that are CD146

Identifiants

pubmed: 32070421
doi: 10.1186/s13287-020-01597-8
pii: 10.1186/s13287-020-01597-8
pmc: PMC7026983
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

66

Subventions

Organisme : NIAMS NIH HHS
ID : K99 AR075899
Pays : United States
Organisme : NIAMS NIH HHS
ID : R00 AR075899
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007171
Pays : United States

Références

Acta Histochem. 2008;110(5):397-407
pubmed: 18272209
Aging (Albany NY). 2011 Oct;3(10):920-33
pubmed: 21990129
Elife. 2014 Sep 25;3:e03696
pubmed: 25255216
J Mater Sci Mater Med. 2008 Jul;19(7):2563-7
pubmed: 17665108
J Anat. 1996 Aug;189 ( Pt 1):9-22
pubmed: 8771392
Osteoarthritis Cartilage. 2009 Apr;17(4):518-28
pubmed: 19010695
Mol Genet Genomics. 2007 Mar;277(3):237-48
pubmed: 17131158
PLoS One. 2010 Oct 14;5(10):e13246
pubmed: 20976230
Stem Cell Rev Rep. 2017 Apr;13(2):299-308
pubmed: 27987073
J Orthop Res. 2015 Jan;33(1):84-91
pubmed: 25266708
Stem Cells. 2014 Jun;32(6):1408-19
pubmed: 24578244
Osteoarthritis Cartilage. 2016 May;24(5):868-72
pubmed: 26687821
Biochem Biophys Rep. 2015 Sep;3:38-44
pubmed: 26900604
Ann N Y Acad Sci. 1990;599:45-57
pubmed: 2221676
Stem Cell Rev Rep. 2015 Apr;11(2):242-53
pubmed: 25578634
Annu Rev Biochem. 1991;60:827-61
pubmed: 1883210
Mol Reprod Dev. 1993 Aug;35(4):368-74; discussion 374-5
pubmed: 7691098
Lab Chip. 2015 Mar 7;15(5):1230-49
pubmed: 25598308
Best Pract Res Clin Rheumatol. 2011 Dec;25(6):815-23
pubmed: 22265263
J Orthop Res. 2005 Mar;23(2):425-32
pubmed: 15734258
Stem Cells. 2019 Jan;37(1):65-76
pubmed: 30378731
Cartilage. 2018 Apr;9(2):171-182
pubmed: 29047310
Cell. 2018 Sep 20;175(1):43-56.e21
pubmed: 30241615
Cell. 2016 Jul 14;166(2):451-467
pubmed: 27419872
J Am Soc Nephrol. 2001 Nov;12(11):2400-10
pubmed: 11675416
Stem Cells Transl Med. 2016 Jun;5(6):733-44
pubmed: 27130221
Histochem J. 1999 Sep;31(9):623-32
pubmed: 10579632
Stem Cell Reports. 2015 Mar 10;4(3):404-18
pubmed: 25733017
Arthritis Rheumatol. 2017 Jan;69(1):9-21
pubmed: 27564539
Arthritis Rheum. 2004 May;50(5):1522-32
pubmed: 15146422
Nature. 2003 May 15;423(6937):332-6
pubmed: 12748651
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19172-7
pubmed: 23115336
Dev Biol. 2012 Jun 1;366(1):2-9
pubmed: 22230617
Circulation. 2010 Jul 6;122(1):80-7
pubmed: 20606130
Sports Health. 2009 Nov;1(6):461-8
pubmed: 23015907
FASEB J. 2015 Aug;29(8):3399-410
pubmed: 25911615
Dev Dyn. 1995 Jul;203(3):363-76
pubmed: 8589433
Biofabrication. 2013 Jun;5(2):025009
pubmed: 23592549
Stem Cell Res Ther. 2018 Jun 19;9(1):166
pubmed: 29921287
Dis Model Mech. 2013 Jul;6(4):896-904
pubmed: 23751357
Differentiation. 2010 Sep-Oct;80(2-3):155-65
pubmed: 20619527
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Osteoarthritis Cartilage. 2015 Nov;23(11):1825-34
pubmed: 26521728
Methods. 2017 May 15;121-122:29-44
pubmed: 28522326
Nat Biotechnol. 2015 Jun;33(6):638-45
pubmed: 25961409
Stem Cell Reports. 2013 Dec 12;1(6):575-89
pubmed: 24371811
Trends Cell Biol. 2001 Mar;11(3):130-5
pubmed: 11306274
Matrix. 1991 Aug;11(4):282-8
pubmed: 1921854
Tissue Eng. 2006 Jul;12(7):1971-84
pubmed: 16889526
Coll Relat Res. 1988 Jul;8(4):277-94
pubmed: 2850886
J Biomech Eng. 1993 Nov;115(4B):460-7
pubmed: 8302026
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Cell. 2007 Nov 30;131(5):861-72
pubmed: 18035408
Arthritis Rheum. 2002 Mar;46(3):694-703
pubmed: 11920405
Circulation. 2010 Mar 9;121(9):1113-23
pubmed: 20176987
Matrix Biol. 2014 Oct;39:5-10
pubmed: 25172830
Matrix Biol. 2018 Oct;71-72:40-50
pubmed: 29800616
Cell Tissue Res. 2002 Jun;308(3):371-9
pubmed: 12107430
Dev Biol. 1989 Feb;131(2):558-66
pubmed: 2643540
FASEB J. 2009 Sep;23(9):3179-92
pubmed: 19447881
Dev Dyn. 2000 Jun;218(2):394-400
pubmed: 10842365
PLoS One. 2017 Jul 6;12(7):e0177962
pubmed: 28683107
Nat Rev Mol Cell Biol. 2013 Jun;14(6):357-68
pubmed: 23673969

Auteurs

Amanda Dicks (A)

Department of Orthopaedic Surgery, Washington University, St. Louis, MO, 63110, USA.
Shriners Hospitals for Children - St. Louis, St. Louis, MO, 63110, USA.
Department of Biomedical Engineering, Washington University, St. Louis, MO, 63110, USA.
Center of Regenerative Medicine, Washington University, St. Louis, MO, 63110, USA.

Chia-Lung Wu (CL)

Department of Orthopaedic Surgery, Washington University, St. Louis, MO, 63110, USA.
Shriners Hospitals for Children - St. Louis, St. Louis, MO, 63110, USA.
Center of Regenerative Medicine, Washington University, St. Louis, MO, 63110, USA.

Nancy Steward (N)

Department of Orthopaedic Surgery, Washington University, St. Louis, MO, 63110, USA.
Shriners Hospitals for Children - St. Louis, St. Louis, MO, 63110, USA.
Center of Regenerative Medicine, Washington University, St. Louis, MO, 63110, USA.

Shaunak S Adkar (SS)

Department of Cell Biology, Duke University Medical Center, Durham, NC, 27710, USA.

Charles A Gersbach (CA)

Department of Biomedical Engineering, Duke University, Durham, NC, 27710, USA.

Farshid Guilak (F)

Department of Orthopaedic Surgery, Washington University, St. Louis, MO, 63110, USA. guilak@wustl.edu.
Shriners Hospitals for Children - St. Louis, St. Louis, MO, 63110, USA. guilak@wustl.edu.
Department of Biomedical Engineering, Washington University, St. Louis, MO, 63110, USA. guilak@wustl.edu.
Center of Regenerative Medicine, Washington University, St. Louis, MO, 63110, USA. guilak@wustl.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH